Combination therapy frameworks represent a critical gap in the NeuroWiki therapeutic pipeline. While single-target approaches have shown limited success in neurodegeneration, emerging evidence demonstrates that targeting multiple pathological mechanisms simultaneously can yield synergistic benefits greater than the sum of individual components. This framework provides a systematic methodology for evaluating, scoring, and prioritizing combination therapy approaches for neurodegenerative diseases.
The Multi-Target Synergy Scoring Framework addresses the fundamental challenge that monotherapies face: neurodegeneration involves multiple interconnected pathways (protein aggregation, neuroinflammation, mitochondrial dysfunction, oxidative stress, impaired autophagy, synaptic loss). Single-target interventions cannot address this network-level pathology, making combination approaches essential for meaningful disease modification.
[Novel Therapy Index](/ideas/novel-therapy-index) | [SIRT1 Activation + NAD+ Precursor Combination Therapy](/ideas/combo-sirt1-nad-epigenetic-metabolic) | [Proteostasis Triad Pulses](/ideas/payload-proteostasis-triad-pulses) | [CD38 Inhibition + NAD+ Precursor Synergy](/ideas/cd38-inhibition-nad-synergy) | [Alzheimer's Disease](/diseases/alzheimers-disease) | [Parkinson's Disease](/diseases/parkinsons-disease) | [Amyotrophic Lateral Sclerosis](/diseases/als-ftd-spectrum) | [Neuroinflammation](/mechanisms/neuroinflammation) | [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway) | [Autophagy Dysfunction](/mechanisms/autophagy-lysosomal-pathway) | [Protein Aggregation](/mechanisms/protein-aggregation-pathway)
The Multi-Target Synergy Scoring Framework evaluates combination therapies across five fundamental pillars:
| Pillar | Score 0-4 | Score 5-7 | Score 8-10 |
|--------|-----------|-----------|------------|
| Mechanistic Synergy | Independent mechanisms, no interaction predicted | Partial pathway overlap or compensatory effects | Strong network-level synergy, predicted emergent benefit >30% |
| Pharmacodynamic Compatibility | Major PK/PD conflicts requiring separate delivery | Moderate compatibility with schedule adjustments | Fully compatible co-formulation possible |
| Biomarker Convergence | No shared biomarkers, separate endpoints required | Partial biomarker overlap, some integration possible | Complete biomarker panel shared across all components |
| Safety Complementarity | Overlapping toxicities, dose reduction required | Non-overlapping but requires monitoring | Complementary safety profiles enable full-dose delivery |
| Translational Feasibility | Major regulatory or development obstacles | Moderate development path with standard approaches | Clear regulatory pathway, established combination precedents |
The Total Synergy Score ranges from 0-50, calculated as the weighted sum:
Total Score = (Mechanistic Synergy × 2.5) + (Pharmacodynamic Compatibility × 1.5) +
(Biomarker Convergence × 1.5) + (Safety Complementarity × 2.0) +
(Translational Feasibility × 1.5)
Interpretation:
| Pillar | Score | Rationale |
|--------|-------|-----------|
| Mechanistic Synergy | 9 | SIRT1 requires NAD+ as cofactor; combination addresses both substrate availability and enzyme activation simultaneously |
| Pharmacodynamic Compatibility | 9 | NMN/NR and SIRT1 activators have complementary PK profiles, can be co-formulated |
| Biomarker Convergence | 8 | Shared endpoints: NAD+/NADH ratio, SIRT1 activity, mitochondrial function markers |
| Safety Complementarity | 8 | Non-overlapping safety profiles; both agents have established safety records |
| Transl. Feasibility | 8 | Multiple clinical trials for both monotherapies; clear regulatory pathway |
Total: 42/50 (Excellent)
| Pillar | Score | Rationale |
|--------|-------|-----------|
| Mechanistic Synergy | 10 | Three parallel proteostasis bottlenecks addressed; compensatory pathway activation predicted |
| Pharmacodynamic Compatibility | 7 | Requires staggered dosing; some schedule optimization needed |
| Biomarker Convergence | 9 | Ubiquitinated protein clearance, ATF4/CHOP markers, chaperone activity all measurable |
| Safety Complementarity | 7 | All three approaches affect protein homeostasis; requires careful monitoring |
| Transl. Feasibility | 7 | Each component has precedents but combination is novel; Phase 1/2 design needed |
Total: 40/50 (Excellent)
| Pillar | Score | Rationale |
|--------|-------|-----------|
| Mechanistic Synergy | 8 | Anti-inflammatory (NLRP3) + pro-phagocytic (CD47) address complementary immune axes |
| Pharmacodynamic Compatibility | 6 | Different cell targets; requires proof of simultaneous engagement |
| Biomarker Convergence | 7 | IL-1β, IL-6, and clearance markers can be jointly assessed |
| Safety Complementarity | 6 | Both affect immune function; infection risk monitoring required |
| Transl. Feasibility | 7 | Both targets in clinical development; combination trials planned |
Total: 34/50 (Good)
| Target Category | Priority | Rationale |
|-----------------|----------|-----------|
| Anti-amyloid + anti-tau | High | Independent pathological drivers; sequential or simultaneous approaches |
| Neuroinflammation + synaptic rescue | High | Inflammation drives synaptic loss; dual intervention critical |
| Metabolic support + proteostasis | Moderate | Age-related decline; lower priority than core pathology |
| Target Category | Priority | Rationale |
|-----------------|----------|-----------|
| Alpha-synuclein + mitochondrial function | High | Core pathological axis in PD |
| Neuroinflammation + dopamine restoration | High | Inflammatory milieu impairs dopamine function |
| LRRK2 + GBA1 | Moderate | Genetic subtypes benefit from pathway-specific approaches |
| Target Category | Priority | Rationale |
|-----------------|----------|-----------|
| TDP-43 + RNA metabolism | High | Core pathology in ALS/FTD |
| Neuroinflammation + excitotoxicity | High | Both contribute to motor neuron loss |
| Proteostasis + nucleocytoplasmic transport | High | Multiple converging mechanisms |
| Target Category | Priority | Rationale |
|-----------------|----------|-----------|
| Senescence + NAD+ restoration | High | Fundamental aging mechanisms |
| DNA repair + mitochondrial biogenesis | High | Age-related decline in cellular maintenance |
| Autophagy + circadian entrainment | Moderate | Cellular cleaning and temporal regulation |